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InﬂammationProtective effects of prostacyclin (PC) or its stable analog beraprost against agonist-induced lung vascular
inﬂammation have been associated with elevation of intracellular cAMP and Rac GTPase signaling which
inhibited the RhoA GTPase-dependent pathway of endothelial barrier dysfunction. This study investigated a
distinct mechanism of PC-stimulated lung vascular endothelial (EC) barrier recovery and resolution of LPS-
induced inﬂammation mediated by small GTPase Rap1. Efﬁcient barrier recovery was observed in LPS-
challenged pulmonary EC after prostacyclin administration even after 15 h of initial inﬂammatory insult and
was accompanied by the signiﬁcant attenuation of p38MAP kinase andNFκB signaling and decreased production
of IL-8 and soluble ICAM1. These effects were reproduced in cells post-treated with 8CPT, a small molecule
activator of Rap1-speciﬁc nucleotide exchange factor Epac. By contrast, pharmacologic Epac inhibitor, Rap1
knockdown, or knockdown of cell junction-associated Rap1 effector afadin attenuated EC recovery caused by
PC or 8CPT post-treatment. The key role of Rap1 in lung barrier restoration was further conﬁrmed in the murine
model of LPS-induced acute lung injury. Lung injurywas monitored bymeasurements of bronchoalveolar lavage
protein content, cell count, and Evans blue extravasation and live imaging of vascular leak over 6 days using a
ﬂuorescent tracer. The data showed signiﬁcant acceleration of lung recovery by PC and 8CPT post-treatment,
which was abrogated in Rap1a−/−mice. These results suggest that post-treatment with PC triggers the Epac/
Rap1/afadin-dependent mechanism of endothelial barrier restoration and downregulation of p38MAPK and
NFκB inﬂammatory cascades, altogether leading to accelerated lung recovery.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Acute respiratory distress syndrome (ARDS) represents a spectrum
of common syndromes in response to a variety of infectious and non-
infectious insults. Until now there remain few effective therapeutic
approaches towards for this devastating illness, mortality rates (30–
40%) remain unacceptably high [1,2], and novel treatments aimed at
reducing vascular leak and acute inﬂammation in lung injury have yetlar lavageﬂuid;ECs,endothelial
em;HPAECs, humanpulmonary
yeloperoxidase; nsRNA, non-
rical resistance; XPerT, express
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(K.G. Birukov).to be developed. Despite the recent progress towards understanding
the basis of increased EC permeability (see [3,4] for review), molecular
events stimulating EC barrier restoration in the course of ALI remain
poorly understood.
Prostaglandins represent an important group of lipidmediatorswith
barrier-protective potential towards the vascular endothelium [5].
While prostaglandin E2 (PGE2) and thromboxanes appear to participate
in the propagation of inﬂammation [6,7], other prostaglandins such as
PGE1 and prostacyclin (PC) exhibit potent protective effects in ische-
mia–reperfusion [8] and ventilator induced lung injury [9]. The beneﬁ-
cial effects of prostaglandins extend beyond their vasodilating effects
and regulation of local circulation and involve direct protective effects
on the vascular endothelium [5,10,11]. Protective effects of PC and its
synthetic analogs, iloprost and beraprost, have been characterized by
several groups [5,11–14].
Elevation of intracellular cyclic AMP (cAMP) levels is amajor cellular
response to PC. In pulmonary vascular endothelia, PC-induced elevation
of cAMP at submembrane compartment promotes enhancement of the
EC barrier [5,11,15]. Barrier-protective effects of cAMP-elevating agents
on EC monolayers have been previously associated with an inhibitory
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Fig. 1. Post-treatment with prostacyclin and 8CPT recovers LPS-induced EC permeability and monolayer disruption. Pulmonary ECs plated on microelectrodes were stimulated with LPS
(300 ng/ml), followed by: A— PC (200 ng/ml); or B— 8CPT (50 μM) post-treatment at different time points after LPS challenge, as shown by arrows. Transendothelial resistance reﬂecting
ECmonolayer barrier properties wasmonitored over 20 h after treatments. Insets in panels A and B show an increase in transendothelial resistance caused by treatment with PC or 8CPT
alone. C and D: Pulmonary ECs grown on glass coverslipswere challengedwith LPS for 5 h, followed by PC or 8CPT treatment for additional 30min, 1 h, or 2 h, as indicated. C— analysis of
actin cytoskeletal rearrangement was performed by immunoﬂuorescence staining with Texas Red phalloidin. Paracellular gaps are marked by arrows. Bar graph represents quantitative
analysis of paracellular gap formation in control and treatedHPAEC. Data are expressed asmean+ SD of four independent experiments; *p b 0.05, vs. LPS alone. D— immunoﬂuorescence
staining for VE-cadherin was performed to visualize adherens junctions. Insets below depict higher magniﬁcation images of VE-cadherin patterns in cell junction areas after different
treatments.
780 A.A. Birukova et al. / Biochimica et Biophysica Acta 1852 (2015) 778–791role of cAMP-activated protein kinase A towards an agonist-induced EC
contractile response mediated by RhoGTPase and myosin light chain
kinase and leading to EC barrier disruption [16–19]. An alternate, PKA-
independent pathway of EC barrier enhancement, involves cAMP-
activated guanine nucleotide exchange factor (GEF) Epac1 and its targetRap1 GTPase, which strengthens the endothelial barrier by de novo
formation or enhancing the existing intercellular adhesive complexes
via its cell adhesion effector afadin [20,21].
It is also important to note that the intracellular location of cAMP
pool critically determines its physiological outcome. While PC-induced
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782 A.A. Birukova et al. / Biochimica et Biophysica Acta 1852 (2015) 778–791generation of cyclic AMP in the subplasma membrane compartment
activates PKA and Epac signaling leading to tightening of cell adhesions,
strengthening of cortical actin cytoskeleton, reduction of actomyosin
contraction, and enhancement of EC barrier described above, expansion
of cAMP from sub-membrane compartment to the cytosolic compart-
ment caused by soluble adenylate cyclases from pathogenic bacteria
disrupts the endothelial barrier through PKA-mediated disassembly of
microtubules [22,23].
Afadin is a scaffold protein activated by small GTPase Rap1, which
promotes the assembly of cadherin-based adherens junctions [24,25],
but also interacts with tight junction protein ZO-1 and adherens
junction proteins α-catenin and p120-catenin. Rap1-induced p120-
catenin association with afadin promotes p120-catenin localization to
the adherens junctions and enhances AJ–TJ interactions in endothelial
cells [26].
In addition, Rap1 activates Rac-speciﬁc guanine nucleotide exchange
factors Tiam1 and Vav2 and promotes the parallel pathway of EC barrier
by stimulating Rac GTPase signaling [11,27]. In contrast to the well
recognized role of Rac1 signaling in endothelial barrier enhancement
and the negative Rac–Rho crosstalk mechanism of EC barrier protection
in the models of agonist-induced permeability, a role of Rap1 signaling
in EC barrier restoration during septic inﬂammation and the link
between cytoskeletal remodeling and modulation of inﬂammatory
signaling in EC remains completely unexplored.
Many experimental models for screening novel protective
compounds utilize preventive or concurrent treatment during ALI
induction, while post-treatment remains the more clinically relevant
intervention. These differences in application of protective agonists
may have a dramatic impact on the outcome and interpretation of mo-
lecularmechanisms contributing to the downregulation or resolution of
ongoing injury in contrast to preventing the initial disruptive signaling
leading to ALI.
In this study we used biochemical, molecular, and functional
approaches to characterize effects of PC post-treatment on the in vitro
and in vivo models of LPS-induced lung injury. Using pharmacologic
inhibitors and activators of Epac, genetic model of Rap1a knockout
mice and Rap1 knockdown in vitro, we investigated a role of Epac–
Rap1 mechanism in the modulation of LPS-induced ALI by PC post-
treatment.2. Materials and methods
2.1. Cell culture and reagents
Humanpulmonary artery endothelial cells (HPAECs) and cell culture
medium were obtained from Lonza Inc (Allendale, NJ), and used at
passages 5–8. Unless speciﬁed, biochemical reagents were obtained
from Sigma (St. Louis, MO). PC and beraprost were obtained from
Cayman (Ann Arbor, MI); 8-(4-chlorophenylthio)-2′-O-methyl-adeno-
sine-3′,5′-cyclic monophosphate (8CPT) and Epac cell permeable
inhibitor ESI-09 were purchased from Calbiochem (La Jolla, CA).
Phospho-p38, IκBα, NFκB, and β-actin antibodies were obtained
from Cell Signaling (Beverly, MA); Rap1, phospho-VE-cadherin, VE-
cadherin, ICAM1, and VCAM1 from Santa Cruz Biotechnology (Santa
Cruz, CA). All reagents for immunoﬂuorescence were purchased from
Molecular Probes (Eugene, OR).Fig. 2. PC and 8CPT post-treatment attenuates LPS-induced EC inﬂammation. Pulmonary ECs w
treatment 30 min after LPS addition followed by 2-h incubation. Phosphorylation of p38 MAP
antibodies. Equal protein loading was veriﬁed by membrane probing with β-actin antibody. B
nuclear translocation was assessed by fractionation assay. Content of NFκB in corresponding t
after LPS addition followed by 19-h incubation. Protein expression of VCAM1 and ICAM1 in stim
braneprobingwithβ-actin antibody. D— PC or 8CPT post-treatment 5 h after LPS addition follow
and F: PC or 8CPTpost-treatment 5 h after LPS addition followedby19-h incubation. E— analysi
without PC or 8CPT post-treatment. F— analysis of PMN adhesion to EC activated by LPSwith or
experiments; *p b 0.05, vs. LPS alone.2.2. Measurement of endothelial permeability
The cellular barrier properties were analyzed by measurements of
transendothelial electrical resistance (TER) across conﬂuent human
pulmonary artery endothelial monolayers using an electrical cell-
substrate impedance sensing system (Applied Biophysics, Troy, NY) as
previously described [28,29].
2.3. Neutrophil migration and adhesion assays
Neutrophil chemotaxis was measured in a 96-well chemotaxis
chamber (Neuroprobe, Gaithersburg, MD) as described previously
[30]. Brieﬂy, freshly isolated neutrophils were placed in a 96-well
chemotaxis chamber and incubated with 200 μl of preconditioned
culturemedia,whichwas collected from stimulated EC cultures. Prelim-
inary experiments have established that the number of cells (4 × 104
cells) used allow the optimal cell migration without clogging the
pores of transwell ﬁlter of the upper chamber. Data were expressed as
percent of cell migration. PMN adhesion to the EC was assessed by
adding the neutrophils freshly isolated from healthy donors to the EC
monolayers grown in the 6-well plates. Neutrophil adhesion on
HPAEC was assessed as described previously [31]. Neutrophil adhesion
data were expressed as percentage of adhesion for all treated groups.
2.4. siRNA transfection
To reduce the content of endogenous Rap1 or afadin, cells were
treated with gene-speciﬁc siRNA duplexes [26,32]. Pre-designed
standard purity siRNA sets (Homo sapiens) were ordered from
Dharmacon (Lafayette, CO), and transfection of EC with siRNA was
performed as previously described [33]. After 48–72 h of transfection,
cells were used for experiments or harvested for western blot veriﬁca-
tion of speciﬁc protein depletion. Nonspeciﬁc, non-targeting siRNA
(Dharmacon, Lafayette, CO) was used as a control treatment.
2.5. Immunoﬂuorescence
Endothelial monolayers plated on glass cover slips were subjected
to immunoﬂuorescence staining as described previously [34]. Slides
were analyzed using a Nikon video imaging system (Nikon Instech
Co., Tokyo, Japan). Images were processed with Image J software
(National Institute of Health, Washington, USA) and Adobe Photoshop
7.0 (Adobe Systems, San Jose, CA) software. Quantitative analysis of
paracellular gap formation was performed as previously described [29,
35,36]. The 16-bit images were analyzed using MetaVue 4.6 software
(Universal Imaging, Downington, PA). The gap formationwas expressed
as a ratio of the gap area to the area of thewhole image. The valueswere
statistically processed using Sigma Plot 7.1 (SPSS Science, Chicago, IL)
software. For each experimental condition at least 10 microscopic ﬁelds
in each independent experiment were analyzed.
2.6. Differential protein fractionation and immunoblotting
Conﬂuent HPAECs were stimulated with LPS with or without PC and
nuclear fraction was isolated using S-PEK kit (EMD Chemicals,
Gibbstown, NJ). Immunoblotting detection of proteins of interest was
performed as described previously [37]. Protein extracts from mouseere challenged with LPS followed by post-treatmentwith PC or 8CPT. A— PC or 8CPT post-
kinase and degradation of IκBα were detected by immunoblotting with corresponding
— PC or 8CPT post-treatment 30 min after LPS addition followed by 2-h incubation. NFκB
otal cell lysates was analyzed to ensure equal loading. C — PC or 8CPT post-treatment 5 h
ulated EC was detected by immunoblotting. Equal protein loading was veriﬁed by mem-
edby 19-h incubation. Secretion of soluble ICAM1and IL-8was evaluated byELISA assay. E
s of PMNmigration stimulated by preconditionedmedium fromEC activated by LPSwith or
without PC or 8CPT post-treatment. Data are expressed asmean+ SDof four independent
783A.A. Birukova et al. / Biochimica et Biophysica Acta 1852 (2015) 778–791lungs or EC were separated by SDS-PAGE, transferred to polyvinylidene
diﬂuoride membranes, and the membranes were incubated with
speciﬁc antibodies of interest. Equal protein loading was veriﬁed by
probing for β-actin. Immunoreactive proteins were detected with the
enhanced chemiluminescent detection system according to the
manufacturer's protocol (Amersham, Little Chalfont, UK).C
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Expression of ICAM1 and VCAM1 was detected by immunoblotting with corresponding antibo
ECs were challenged with LPS with or without post-treatment with PC, with or without Epac i2.7. Measurement of cytokines and chemokines
The concentrations of KC in mouse bronchoalveolar lavage (BAL)
ﬂuid samples were measured using a Mouse Cytokine Multiplex Panel
according to the manufacturer's protocol (Millipore, Billerica, MA). For
interleukin-8 (IL-8) and soluble ICAM1 (sICAM1) measurements inime (hr)
2010 15
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LPS+Epac1-i/PC
Vehicle
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LPS+Epac1-i
EC inﬂammation and hyperpermeability. Pulmonary ECswere challengedwith LPS follow-
ac inhibitor were added 30min after LPS challenge and cells were incubated for additional
inhibitor were added 5 h after LPS challenge and cells were incubated for additional 19 h.
dies. Equal protein loading was veriﬁed by probing with β-actin antibody. C— pulmonary
nhibitor at the times indicated by arrows, and TER was measured over 20 h.
784 A.A. Birukova et al. / Biochimica et Biophysica Acta 1852 (2015) 778–791preconditionedmediumof humanpulmonary EC cultures, supernatants
from treated EC were collected and centrifuged to remove debris. IL-8
and sICAM1 levels were determined by ELISA (R&D Systems, Minneap-
olis, MN) following the manufacturer's protocol. Absorbance was read
at 450 nmwithin 30 min in a microplate reader (Thermomax; Molecu-
lar Devices, Menlo Park, CA).
2.8. Animal studies
All animal care and treatment procedures were approved by the
University of Chicago Institutional Animal Care and Use Committee.
Animals were handled according to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. Rap1a−/− mice
have been described elsewhere [38,39]. C57BL/6J mice were purchased
from Jackson Laboratories (Bar Harbor, ME). Bacterial lipopolysaccha-
ride (LPS, 0.63 mg/kg body wt; Escherichia coli O55:B5) or sterile
water was injected intratracheally in a small volume (20–30 μl) using
a 20-gauge catheter (Exelint International, Los Angeles, CA). Beraprost
(20 μg/kg), 8CPT (20 μM/kg) or sterile saline solutionwas administrated
5 h after LPS instillation by intravenous injection in the external jugular
vein. These doses have been selected based on results of pilot studies,
which showed potent anti-inﬂammatory and barrier protective effects
of PC and 8CPTwithout visible adverse effects on experimental animals.
After 18 h of LPS challenge, animals were sacriﬁced by exsanguinationA
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Fig. 4. Rap1 knockdown attenuates PC-induced ECmonolayer recovery and attenuation of inﬂa
siRNA or non-speciﬁc RNA 48 h prior to LPS treatment followed by PC post-treatment (5 h after
orescence staining for F-actin with Texas Red phalloidin. VE-cadherin was detected by staining
(green) staining. Arrows indicate intercellular gaps. Results are representative of three indep
RNA 48 h prior to LPS treatment followed by PC or 8CPT post-treatment (5 h after LPS) and
VCAM1 was detected by immunoblotting with corresponding antibodies. Equal protein loadin
ﬁrmed by membrane probing with Rap1 antibody.under anesthesia. BAL was performed using 1 ml of sterile Hanks
balanced salt buffer and measurements of cell count and protein
concentrationwere conducted as previously described [40]. For analysis
of LPS-induced lung vascular leak, Evans blue dye (30 ml/kg) was
injected into the external jugular vein 2 h before termination of the
experiment.Measurement of Evans blue accumulation in the lung tissue
was performed by spectroﬂuorimetric analysis of lung tissue lysates
according to the protocol described previously [41,42]. For histological
assessment of lung injury, the lungs were harvested without lavage
collection and ﬁxed in 10% formaldehyde. After ﬁxation, the lungs
were embedded in parafﬁn, cut into 5-μm sections, and stained with
hematoxylin and eosin. Sections were evaluated at 40× magniﬁcation.2.9. In vivo optical imaging
Mice were injected with 100 μl of 2 nmol Angiosense 680 EX (a
vascular ﬂuorescent blood pool imaging agent purchased from
PerkinElmer, Inc., Boston, MA; cat# NEV10054EX), intravenously via
tail vein. After 24 h, ﬂuorescent optical imaging was performed in the
Integrated Small Animal Imaging Research Resource (iSAIRR) at the
University of Chicago using Xenogen IVIS 200 Spectrum (Caliper Life
Sciences. Alameda, CA). Mice were exposed to isoﬂurane anesthesia
with O2 through the gas anesthesia manifold and placed on the imagingsi-Rap1: LPS + PC
si-Rap1
Veh LPS
LPS+
PC
LPS+
8CPT
mmation caused by LPS. A— ECs plated on coverslips were transfected with Rap1-speciﬁc
LPS) and additional 1-h incubation. Cytoskeletal remodeling was assessed by immunoﬂu-
with VE-cadherin antibody. Shown are merged images of F-actin (red) and VE-cadherin
endent experiments. B — ECs were transfected with Rap1-speciﬁc siRNA or non-speciﬁc
additional 19-h incubation. VE-cadherin phosphorylation and expression of ICAM1 and
g was veriﬁed by membrane probing with β-actin antibody. Depletion of Rap1 was con-
785A.A. Birukova et al. / Biochimica et Biophysica Acta 1852 (2015) 778–791stage. Acquisition and image analysis were performed with Living
Image 4.3.1 Software.
2.10. Statistical analysis
Results are expressed as means ± SD of three to eight independent
experiments. Stimulated samples were compared to controls by
unpaired Student's t-test. For multiple-group comparisons, one-way
ANOVA and Tukey's post hoc multiple-comparison test were used.
p b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Effects of PC post-treatment on LPS-induced endothelial hyper-
permeability and disruption of monolayer integrity
Treatment of ongoing inﬂammation with protective compounds
represents a more clinically relevant scenario of pharmacological
intervention. Therefore, in the following studies we evaluated the
effects of PC post-treatment in the model of EC barrier dysfunction
and inﬂammation induced by LPS. PC added after 30 min, 2 h, 5 h or
15 h of LPS stimulation exhibited potent barrier protective effects
reﬂected by pronounced and sustained elevation of transendothelial
electrical resistance (TER) (Fig. 1A).
Because previous studies by our group described a role for small
GTPase Rap1 activated by Rap1-speciﬁc guanine nucleotide exchange
factor Epac in the direct effect of PC on EC barrier [11], we examined a
role of the Epac–Rap1 pathway in barrier recovery of LPS-challengedB
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Fig. 5. Afadin knockdown attenuates protective effects of PC post-treatment on ECmonolayer r
transfected with afadin-speciﬁc siRNA or non-speciﬁc RNA 72 h prior to LPS treatment followed
tected by staining with VE-cadherin antibody. Arrows show sites of VE-cadherin disappearance
were transfectedwith afadin-speciﬁc siRNA or non-speciﬁc RNA 72 h prior to LPS treatment foll
sion of ICAM1 and VCAM1 in control and afadin-depleted EC was detected by immunoblotting
with β-actin antibody. Depletion of afadin was conﬁrmed by membrane probing with afadin aEC monolayers. In these experiments, LPS-challenged ECs were treated
with selective Epac activator, 8CPT, and the EC permeability response
was monitored by measurements of TER. Post-treatment with 8CPT 30
min–15 h after LPS challenge caused recovery of EC barrier (Fig. 1B).
Recovery of LPS-induced EC barrier failure by PC post-treatment
monitored by TER measurements was further linked to cytoskeletal
changes. EC stimulation with LPS for 5 h caused the formation of actin
stress ﬁbers (Fig. 1C), disruption of the continuous line of VE-cadherin
positive paracellular adherens junctions (Fig. 1D) and the appearance
of paracellular gaps reﬂecting compromised EC barrier. Remarkably,
the addition of PC after 5 h of LPS treatment caused reduction of stress
ﬁbers and restoration of the continuous adherens junction pattern
accompanied by the resealing of paracellular gaps observed 30 min–
2 h after PC or 8CPT post-treatment (Fig. 1C, D). The bar graph repre-
sents results of quantitative analysis of PC and 8CPT post-treatment
effects on LPS-induced gap formation.
3.2. PC post-treatment suppresses LPS-induced EC inﬂammatory activation
We investigated the effects of PC and 8CPT post-treatment on LPS-
induced activation of inﬂammatory signaling. EC exposure to LPS for
2.5 h caused pronounced phosphorylation/activation of p38 MAP
kinase, degradation of the IκBα inhibitory subunit (Fig. 2A), and nuclear
translocation of NFκB (Fig. 2B) required for inﬂammatory gene expres-
sion. These effects were suppressed by post-treatment with PC or 8CPT
30 min after LPS challenge.
At later time points (24 h), LPS increased expression of ICAM1 and
VCAM1, the adhesion molecules involved in EC–neutrophil interaction,si-Afadin: LPS + PC
si-Afadin
Veh LPS
LPS+
PC
LPS+
8CPT
ecovery and attenuation of inﬂammation caused by LPS. A— ECs plated on coverslips were
by PC post-treatment (5 h after LPS) and additional 1-h incubation. VE-cadherin was de-
from cell junctions. Results are representative of three independent experiments. B— ECs
owed by PC or 8CPT post-treatment (5 h after LPS) and additional 19-h incubation. Expres-
with corresponding antibodies. Equal protein loading was veriﬁed by membrane probing
ntibody.
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effects (Fig. 2C). Similar effects were observed in experiments with
8CPT post-treatment.
In complementary studies we measured the production of soluble
ICAM1 (sICAM1) and neutrophil chemoattractant cytokine IL-8. The
addition of PC 5 h after LPS challenge markedly attenuated sICAM1
and IL-8 production by pulmonary EC detected in the preconditioned
culture medium 24 h after LPS addition (Fig. 2D). Similar effects were
observed in cells post-treated with 8CPT.
Activation of the vascular endothelium by inﬂammatory agents
stimulates neutrophil adhesion to the EC lining the vascular luminal
surface and following neutrophil transmigration through the EC
monolayer leading to neutrophil recruitment to the inﬂamed lungA
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ly, neutrophil migration stimulated by preconditioned medium from
LPS-stimulated EC (Fig. 2E) and EC–neutrophil interactions (Fig. 2F)
were signiﬁcantly attenuated by post-treatment with PC or 8CPT 5 h
after LPS addition.
3.3. Rap1 pathway is involved in EC recovery upon PC post-treatment
Our recent study demonstrated a role of Rap1 signaling during EC
barrier restoration after thrombin-induced increase in EC permeability
[32]. The following experiments tested involvement of the Rap10
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restoration in LPS-challenged pulmonary EC caused by PC post-
treatment.
Inhibition of PC-induced Rap1 activation was ﬁrst achieved by cell
pretreatment with the Epac1 inhibitor, which blocked PC-induced
activation of the Epac1–Rap1 pathway. Such inhibition of Epac1–Rap1
abolished the anti-inﬂammatory effect by PC reﬂected by attenuation
of LPS-induced IkBa degradation (Fig. 3A) and ICAM1 and VCAM1
expression (Fig. 3B). EC incubation with Epac1 inhibitor did not signiﬁ-
cantly affect LPS-induced degradation of IkBa inhibitory subunit and
increase in ICAM1 and VCAM1 expression. Inhibition of Epac1 also
prevented the restoration of the EC barrier caused by PC post-
treatment of LPS-challenged EC (Fig. 3C).
The role of Rap1 in EC barrier restoration induced by PC post-
treatment was further assessed in experiments with siRNA-mediated
Rap1 knockdown. Increased VE-cadherin peripheral staining caused
by PC post-treatment (1 h after LPS), which reﬂects restoration of
cell–cell adhesions in LPS-treated cells (Fig. 4A, left panel)was attenuat-
ed in Rap1-depleted lung EC monolayers, which also exhibited
increased paracellular gap formation (Fig. 4A, right panel, shown by
arrows).
VE-cadherin phosphorylation at Y731 is known to promote disassem-
bly of the adherens junction complexes [43,44]. Post-treatment with PC
or 8CPT (5 h after LPS) attenuated LPS-induced VE-cadherin phosphor-
ylation at Y731, and also blocked expression of ICAM1 and VCAM1
(Fig. 4B). Rap1 knockdown by gene-speciﬁc siRNA abolished the
protective effects of PC and 8CPT post-treatment.
The role of the Rap1 pathway in the mediation of PC anti-
inﬂammatory response was further investigated in experiments with
inhibition of Rap1 cytoskeletal target afadin, involved in formation of
cell–cell adhesive complexes [45,46]. siRNA-induced knockdown of
afadin blocked the protective effects of PC post-treatment against LPS-
induced disruption of VE-cadherin positive adherens junctions
(Fig. 5A) and inﬂammatory signaling monitored by increased ICAM1
expression (Fig. 5B). These data suggest the key role of the Rap1–afadin
axis in the mediation of PC effects on EC barrier restoration after an
inﬂammatory insult. A role of the PC–Rap1 axis in tissue barrier restora-
tion after inﬂammatory challenge was further evaluated in animal
models.C
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experiments was conﬁrmed by determination of β-actin content in tissue samples.3.4. Time course image analysis of PC post-treatment effects on lung
recovery after LPS-induced injury
Lung vascular leak in mice treated with LPS and the stable PC
analog beraprost was monitored in the same animals prospectively,
1, 2, 3, and 6 days after treatment. Angiosense 680 EX tracer was
injected intravenously, and tracer accumulation in the lungs
reﬂecting lung vascular barrier dysfunction and lung injury was
performed in anesthetized animals using the non-invasive ﬂuores-
cence optical imaging approach described in the Materials and
methods section. Accumulation of the ﬂuorescent tracer reﬂecting
lung inﬂammation and vascular barrier compromise was observed
24 h after LPS injection, reaching maximal levels at day 2 and
gradually declining by day 6 (Fig. 6A). Importantly, lung dysfunction
was noticeably reduced in mice post-treated with beraprost 5 h after
LPS challenge, and recovery of lung function occurred earlier than in
mice without PC post-treatment. The results were supported by
quantitative analysis of lung imaging data.
Results of live imaging studies were supported by conventional
analysis of bronchalveolar lavage protein content and cell counts in
parallel experiments. Intravenous injections of PC or 8CPT after 5 h of
LPS instillation signiﬁcantly decreased BAL protein content and total
cell count, in the LPS-treated mice (Fig. 6B).3.5. PC post-treatment effectively suppresses LPS-induced lung barrier
dysfunction and inﬂammation in vivo
Effects of PC post-treatment on the lung vascular leak induced by LPS
were further evaluated by measurements of Evans blue extravasation
into the lung tissue. Administration of beraprost signiﬁcantly reduced
LPS-induced Evans blue accumulation in the lung parenchyma
788 A.A. Birukova et al. / Biochimica et Biophysica Acta 1852 (2015) 778–791(Fig. 7A, B). In agreement with cell culture studies, beraprost post-
treatment inhibited LPS-induced ICAM1 expression (Fig. 7C) in the
lung detected by western blot analysis of lung tissue homogenates.3.6. Rap1mediates improved recovery of LPS-induced lung injury caused by
PC post-treatment
Although the Rap1b genetic variant of the Rap1 protein is expressed
in vascular endothelium at higher levels [47], the vascular endothelial
barrier function is more sensitive to depletion of the Rap1a variant
[48,49]. The role of Rap1 in the lung recovery after inﬂammatory insult
was evaluated using the geneticmodel of Rap1a−/−mice. First, we eval-
uated the magnitude of LPS-induced lung injury in Rap1a−/− mice.
Parameters of lung injury in Rap1a−/− mice and matching controls
were analyzed at days 1, 2, 3, 5, and 7 after LPS administration. In com-
parison to wild type controls, Rap1a−/− mice developed more severe
lung injury in response to LPS which was reﬂected by measurements
of protein content (Fig. 8A) and cell counts (Fig. 8B) in BAL samples
from LPS-challenged wild type and knockout animals. Western blot
analysis of lung tissue samples revealedmore prominent ICAM1 expres-
sion in Rap1a−/−mice at day 5 after LPS challenge (Fig. 8C).A
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Rap1a−/− mice and matching controls were injected with vehicle or
beraprost 5 h after the LPS challenge. Protective effects of PC post-
treatment against LPS-induced increases in BAL cell count and protein
content observed in wild type controls were abolished in Rap1a−/−
mice (Fig. 9A).
Histological analysis of lung tissue sections stained with hematoxy-
lin and eosin showed that in contrast to wild type controls, the protec-
tive effects of PC against LPS-induced alveolar wall thickening and
increased leukocyte inﬁltration were diminished in the Rap1 knockout
mice (Fig. 9B). Attenuation of LPS-induced ICAM1 expression by
beraprost was observed in wild type controls and was abolished in
Rap1a−/− mice (Fig. 9C). Next, effects of PC on LPS-induced cytokine
production were tested in control and Rap1a−/− mice. In consistence
with in vitro results, protective effect of beraprost against LPS-induced
elevation of mouse IL-8 homologue KC was suppressed in the Rap1
knockout animals (Fig. 9D). Taken together, these results demonstrate
pronounced anti-inﬂammatory and barrier-protective effects of PC
post-treatment in the animal model of LPS-induced lung inﬂammatory
injury and vascular leak and emphasize a key role of Rap1 in the medi-
ation of PC protective effects.*
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The main ﬁnding of this study is a role of Rap1 signaling in
attenuation of ongoing lung inﬂammation and barrier dysfunction in a
septicmodel of ALI. This is also theﬁrst demonstration of a dramatic im-
provement of EC barrier function and ongoing lung injury achieved by
post-treatment with PC and its stable analogs.
Many models of post-treatment show a relatively short efﬁcient
therapeutic window (10–30 min of post-treatment) effective to inacti-
vate an injurious stimulus [50–52]. The PC pretreatment used in this
study efﬁciently attenuated parameters of lung inﬂammation andA
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as mean + SD of four independent experiments; *p b 0.05.accelerated EC barrier recovery even when it was administered 15 h
after LPS challenge in vitro and 5 h after LPS challenge in vivo. In addi-
tion to analysis of BAL parameters of lung injury, we monitored the
time course of lung vascular leak in control and PC-treated mice with
LPS-induced ALI using a non-invasive live imaging approach. Live
imaging of LPS-induced ALI in mice with or without PC post-treatment
has been performed for the ﬁrst time and demonstrated a signiﬁcant ac-
celeration of lung recovery by PC post-treatment. Tracking the time
dependent changes in the same animal in the course of ALI is a powerful
approach aimed to diminish individual variability in the magnitude
of inﬂammatory response to an intervention. This analysis wasRap1a -/-
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strated high consistence of traditional parameters of ALI and live
imaging data.
PC post-treatment caused remarkably rapid and potent recovery of
barrier function in LPS-challenged EC. Importantly, the recovery effect
of PC was reproduced by cell pretreatment with a speciﬁc activator of
Epac–Rap1 signaling, 8CPT. The time course of EC barrier recovery
suggests Rap1-induced activation on vascular EC cytoskeleton and
restoration of the cell junction barrier as a leadingmechanismof EC bar-
rier recovery caused by PC post-treatment. Besides direct stimulation of
cell junction assembly, Rap1 also promoted re-sealing of intercellular
gaps in EC monolayers stimulated with thrombin [32]. These Rap1
effects had been associated with Rap1-dependent downregulation of
Rho signaling via Rap1-induced Rac1–RhoA negative crosstalk. Rap1
activation in thrombin-treated pulmonary EC represented the mecha-
nism of endothelial barrier auto-recovery and was mediated by the
Rap1-speciﬁc guanine nucleotide exchange factor C3G stimulated by
thrombin-activated Src kinase [32]. The rapid EC barrier recovery
observed in this study suggests activation of similar mechanisms in a
distinct model of EC barrier dysfunction caused by bacterial pathogens.
In addition to the rapid barrier recovery driven by cytoskeletal and
cell junction remodeling, Rap1 activation by PC and 8CPT also blocked
the LPS-induced inﬂammatory response. After binding to a LPS ligand,
TLR4 sequentially recruits the adaptor molecules MyD88, IL-1R-
associated kinase (IRAK), and TNF receptor-associated factor 6
(TRAF6). These adaptor molecules then activate MAP kinases JNK, p38,
ERK1/2 and IκB, a cytoplasmic inhibitor of NFκB [53]. NFκB and MAP
kinases mediate the LPS-induced production of proinﬂammatory cyto-
kines. However, besides the canonical activation by the TLR4-MyD88-
IRAK-TRAF6 cascade, the p38 MAPK and NFκB activity is positively
regulated by the small GTPase, RhoA [54,55]. In turn, inhibition of the
Rho pathway attenuated the inﬂammatory and barrier disruptive EC
response to bacterial pathogens [56–60]. Rap1-mediated attenuation
of Rho signaling described above in the model of thrombin-induced
EC permeability [32], as well as downregulation of Rho-dependent
lung injury by Rap1 activity in the animal model of ventilator-induced
vascular leak [14] suggests a potential mechanism of ALI attenuation
by Rap1–Rho negative crosstalk.
This study also shows attenuation of LPS-induced ICAM1 expression
by the Epac–Rap1 mechanism. ICAM-1 is essential for stable adhesion
and transmigration of leukocytes in most types of inﬂammatory
processes. Blocking antibodies against ICAM-1 inhibit leukocyte
adhesion, while the deletion of the cytoplasmic domain of ICAM-1
completely blocks neutrophil transmigration but not the adhesion,
demonstrating the importance of ICAM-1-dependent signaling in
mediating neutrophil transmigration [61]. Engagement of ICAM-1 by
leukocytes results in tyrosine phosphorylation of VE-cadherin, which
is required for efﬁcient neutrophil TEM. Interestingly, ICAM-1 engage-
ment leads to phosphorylation of VE-cadherin on tyrosines 658 and
731, which correspond to the p120-catenin and β-catenin binding
sites, respectively. Such VE-cadherin phosphorylationmay be mediated
by tyrosine kinases, Src and Pyk2 [62], or by a RhoA-dependent mecha-
nism [63] and promotes disassembly of the VE-cadherin–catenin
complex and internalization of VE-cadherin and p120-catenin leading
to disassembly of adherens junctions and EC barrier compromise. LPS-
induced disruption of adherens junctions associated with tyrosine
phosphorylation of VE-cadherin was also observed in the current
study. One consequence of AJ disassembly is EC barrier compromise
leading to an inﬂux of solutes and increased neutrophil inﬁltration
into the lung, the process that perpetuates ongoing ALI.
Another consequence of AJ disassembly is the release of p120-
catenin from cell junctions. In the context of LPS-induced lung inﬂam-
mation, p120-catenin displacement from AJ and degradation may
propagate inﬂammatory signaling. Molecular inhibition of p120-
catenin has been associated with development of skin inﬂammation in
p120-catenin knockout mice due to dysregulation of Rho signaling atcell–cell junctions [64]. Downregulation of p120-catenin in lung EC
increased the inﬂammatory response of LPS and the mortality in the
animal LPS-induced sepsis model [65]. These effects were associated
with p120-catenin modulation of lung immune function by interfering
with the association of TLR4 with its adaptor MyD88 to block TLR4
signaling and NFκB activation in endothelial cells.
Our data show that pharmacologic inhibition of Epac, Rap1 knock-
down in pulmonary EC, or Rap1a knockout in mice exacerbated LPS-
induced lung injury. Interestingly, protective effects of PC and 8CPT
against LPS-induced adherens junction disassembly, EC barrier disrup-
tion and ICAM1 expression were attenuated by the knockdown of
Rap1 effector afadin. Afadin involvement in regulating the expression
of inﬂammatory molecules is a novel ﬁnding. Howmay afadin be possi-
bly involved in Rap1 anti-inﬂammatory signaling? Afadin mediates the
formation of nascent adherens junctions and directly interacts with
cadherin-associated signaling protein p120-catenin [66]. Barrier
enhancing signals stimulate afadin interaction with AJ and TJ protein
partners. p120-catenin and ZO-1 [25,26], which leads to the strengthen-
ing of cell–cell junctions and enhancement of EC barrier integrity. Based
on the previous reports and current data, we suggest that, as a Rap1
effector and adaptor protein, afadin preserves p120-catenin localization
at adhesive complexes in PC-stimulated cells thus preventing p120-
catenin from degradation and initiation of the TLR4-MyD88-NFκB
inﬂammatory cascade described above. These data suggest a novel
role for Rap1 signaling in the modulation of the EC innate immune
response to bacterial pathogens via a Rap1–afadin-dependent
mechanism.
In conclusion, this is the ﬁrst study demonstrating the anti-
inﬂammatory effects of Rap1–afadin axis in the models of LPS-induced
lung injury. This study proposes a novel paradigm of dual Rap1–
afadin-mediated anti-inﬂammatory mechanisms in ALI, which include:
a) re-sealing of intercellular junctions leading to enhanced EC barrier
and reduced transfer of inﬂammatory molecules to the lung parenchy-
ma; and b) inhibition of EC inﬂammatory activation (manifested by
activation of cell adhesion molecules and cytokine expression). Beneﬁ-
cial effects of speciﬁc activators of Rap1 signaling on ALI recovery may
have a substantial impact on the drug design strategies leading to the
generation ofmore effective or tissue-speciﬁc Rap1 activators. As vascu-
lar barrier-protective and anti-inﬂammatory therapeutic beneﬁts of PC
are currently offset by hypotensive side effects, the potential utilization
of Epac and Rap1 activators may overcome the disadvantages of
currently available PC analogs. In the future, attempts to develop efﬁ-
cient small molecule Rap1 activators may provide a novel aspect of
treatment of ARDS and other conditions associated with inﬂammation
and vascular barrier dysfunction.Acknowledgments
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